Background: Ultra-deep sequencing (UDS) allows detection of minority resistant variants (MRVs) with a threshold of 1% and could be useful to identify variants harbouring single or multiple drug-resistance mutations (DRMs).
Introduction
Population-based sequencing (as Sanger sequencing) has weak sensitivity in detecting drug-resistance mutations (DRMs) present in < 20% of the viral population. It identifies a consensus sequence without the determination of the link between mutations. Ultradeep sequencing (UDS) has been proved valuable in detecting minority resistant variants (MRVs) with a threshold of 1% during the course of virological failure. 1 Moreover, the presence of MRVs at baseline has been shown to be a risk factor for subsequent virological failure. 2, 3 UDS on long fragments is also useful in studying the diversity and evolution of a quasispecies. 4 Thus, it could be advantageous to study the dynamics of selection of resistant variants during the course of virological failure. The objective of this work was to analyse longitudinally the integrase gene region using UDS in a 3-year-old boy rapidly failing a raltegravir based-regimen.
Methods

Ethics
This was a non-interventional study without additional sample to usual procedures. Information was given to the participants and a 'non-opposition' statement was obtained. Sequencing HIV-1 RNA or DNA was extracted from 200 lL of either plasma or whole blood samples using automated extraction methods with a NucliSENS
Etoile, France) or QIAsymphony (Qiagen, Les Ulis, France), respectively. Sanger sequencing was performed on the reverse transcriptase and integrase regions using Abbott Viroseq kits (Abbott Rungis, France). UDS was performed on both regions as described elsewhere. 1 Briefly, after an initial reverse transcription for RNA extracts, integrase was amplified by PCR (Titan One Tube RT-PCR Kit, Roche Applied Science) with primers IN12 and IN13. 5 A nested PCR was performed with High Fidelity Platinum Taq DNA Polymerase (Invitrogen), using primers containing a multiplex identifier (MID) and target DNA 5 0 -CTGCCACCTGTAGTAGCAAA-3 0 and 5 0 -ACTGCCATTTGTACTGCTGTC-3 0 . Primers were specifically designed to allow amplification of a unique fragment of the subtype C integrase (from nucleotide 82 to nucleotide 539, relative to HXB2). Pyrosequencing was performed according to the manufacturer's recommendations with a GS Junior system (Roche 454 Life Sciences). 6 
Genotypic resistance interpretation
Resistance mutations were interpreted using the September 2016 ANRS rules (http://www.hivfrenchresistance.org, V26). The GS Amplicon Variant Analyzer (AVA) was used to analyse the UDS results. 2 Mutations with a frequency of 1% were considered. A Python script was then used to summarize the different combinations of linked mutations on the same fragment for each read (available on demand).
Evolution analysis
We built the haplotypes present in each sample using the reconstruction algorithm implemented in QuRe. 7 The analysis of the proportions of resistance variants in each sample corroborated the previous analysis. Then, we reconstructed the temporal dynamics of the viral haplotypes using a Bayesian Markov chain Monte Carlo analysis in BEAST, 8 with an HKY substitution model and a strict molecular clock.
Results
Patients
We investigated the case of an HIV-positive child, diagnosed at 3 years of age, who started a raltegravir-based ART containing abacavir and lamivudine. Contrary to his mother, the viral load did not decrease significantly (Table 1 and Figure 1a ), from 6.22 to 5.77 log 10 copies/mL after 17 weeks of ART. Both the mother and the child were infected by the same subtype C virus, with resistance to NNRTI at baseline. Sanger sequencing revealed the rapid emergence of major DRMs N155H and E92Q to raltegravir, as well as an M184V resistance to lamivudine/emtricitabine. Raltegravir was switched to darunavir at week 19, leading to a decrease in viral load.
UDS and linkage between integrase inhibitors (INIs) DRMs
The dynamics of resistance to INIs was studied using Sanger sequencing and UDS on longitudinal plasma samples at baseline (BL) and weeks 4, 8, 13 and 17 after treatment initiation. Plasma HIV-1 RNA and whole blood HIV-1 DNA were also analysed at week 39 to look for the persistence of the major DRMs 4 months after the switch to darunavir. The baseline plasma sample of the mother was examined as well. In-depth amplification (6000-16 000 reads per sample) of long sequences (mean, 405 nucleotides) allowed us to study the link between mutations and quasispecies evolution.
In Sanger sequencing and UDS, no MRV to INIs was detected in the mother and child at baseline (Table 1 and Figure 1a) . Sanger sequencing identified the selection of mutations E92Q and N155H at week 8. They persisted to week 17, when the additional mutation Y143R was also detected. Using UDS, mutation N155H was detected at week 4 in 4% of the sequences. At week 8, 90% of the viral population carried N155H, including 16% with the E92Q accessory mutation. The double mutant E92Q þ N155H became the major variant at week 13 (57%). Y143R emerged at week 17, leading to different resistance mutations patterns: single mutants N155H (47%) and Y143R (22%), and double mutants E92Q þ N155H (13%), Y143R þ N155H (2%) and E92Q þ Y143R (2%). No major DRM was detected in plasma RNA at week 39, 4 months after raltegravir was switched. However, N155H was archived in the cell-associated HIV-DNA, where it represented 14% of the sequences.
Overall, the E92Q mutation appeared after the N155H mutation and was almost exclusively associated with N155H. Using a Bayesian approach based on reconstructed haplotypes, we showed that the double mutant most likely emerged from an N155H-carrying ancestor, while single E92Q formed a different clade (Figure 1c) .
Regarding the reverse transcriptase mutation profile, UDS was in line with Sanger sequencing, detecting the emergence of M184V by week 8 in 75% of the population and up to >99% by week 17.
Finally, we wondered whether our linkage approach could provide further insights into the selection of accessory integrase mutations. The most prevalent were T97A, G163R and V72I, representing 16%, 15% and 8% at week 17, respectively (data not shown). Interestingly, a polymorphism at position 50 (methionine or isoleucine) was found to evolve to a much larger extent, representing 12% of the variants at baseline but up to 57% of the variants at week 13 ( Figure 1b) . The linkage analysis revealed that M50I was present in 40% of N155H variants and 80% of E92Q þ N155H variants at weeks 8, 13 and 17 (Figure 1a) . After the switch to darunavir, M50I returned to 14% of the variants in RNA but was detected in 57% of variants in cell-associated DNA.
Discussion
The rapid escape to raltegravir in this 3-year-old HIV-infected child was not due to pre-existent integrase MRVs, but to a rapid selection of the N155H mutation within 4 weeks followed by the addition of the E92Q mutation soon after. Stefic et al. Integrase resistance dynamics by UDS JAC E92Q þ N155H, conferring resistance to the whole INI class, including dolutegravir, emerged at week 8 and became dominant thereafter. The selective pressure exerted by raltegravir also led to the emergence of Y143R, including different double mutants with unknown phenotypic impact. N155H is one of the three major resistance pathways to raltegravir and is known to emerge faster due to limited phenotypic impact on integrase functionality. [9] [10] [11] It is often replaced by Q148R or Y143R variants thereafter, as seemed to be the case for this patient. E92Q does not improve viral fitness but the double mutant E92Q þ N155H decreases raltegravir phenotypic susceptibility >10-fold compared with N155H alone. 12 Our longitudinal linkage analysis and evolutionary approach suggest that both mutations do not coevolve in different variants that recombine, but rather that E92Q is selected on N155H variants. This case study illustrates the usefulness of UDS in detecting early MRVs and determining the dynamics of emergence of various HIV-1 resistance patterns in longitudinal analysis.
A possible limitation of this work is the risk of resampling during PCR steps. However, considering the high viral load and the good concordance of our results with present knowledge on integrase resistance, we considered it negligible. Future investigation should nevertheless anticipate this problem with tools such as primer ID and bioinformatic pipelines. 13 Applying our approach to accessory mutations, we identified V72I, T97A, G163R and M50I. G163R was associated with Y143R as expected. Interestingly, 75% of T97A were linked to N155H and 25% to Y143R. T97A is known to further decrease the susceptibility to raltegravir of subtype B viruses in association with Y143R. The occurrence of resistance mutation profile is dependent on the baseline integrase context 5 and T97A could better fit with N155H in subtype C integrase. M50I is a polymorphic mutation present on 10% of subtype B viruses but up to 42% of subtype C, based, respectively, on 4011 and 1106 clinical isolates from treatment-naive patients from the Stanford HIV Drug Resistance Database (last review, July 2016). It has recently been shown to confer increased resistance to dolutegravir in association with R263K. 14 We showed that M50I increased under selection pressure by raltegravir. Our linkage analysis revealed that M50I was preferentially associated with E92Q þ N155H and N155H variants. It could confer greater resistance to raltegravir or/and rescue the viral fitness of the enzyme. The phenotypic impact of this polymorphism on raltegravir and dolutegravir susceptibility, in association with E92Q and N155H, should be investigated, as well as its role in the selection of these mutations in the context of subtype C integrase. There are only limited data on resistance to INIs regarding subtype C viruses, the most prevalent subtype worldwide (only four clinical isolates in the Stanford HIV Drug Resistance Database). Raltegravir is nonetheless recommended as a second-line regimen for children in the WHO November 2015 guidelines and the use of INIs will probably increase in world regions where subtype C is dominant and multidrug resistance is also prevalent.
